[{"address1": "3204\u20134464 Markham Street", "city": "Victoria", "state": "BC", "zip": "V8Z 7X8", "country": "Canada", "phone": "250-483-0308", "website": "https://www.ipatherapeutics.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "ImmunoPrecise Antibodies Ltd. operates as a biotherapeutic research and technology company in Canada, the United States, Europe, Canada, Australia, and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; peptide production for subsequent antibody discovery campaign; B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. In addition, it provides phage display, a custom immune library from multiple species; CAR development, an adaptable antibody, which allows the inclusion of functional data early in the screening funnel; antibody sequencing; and assay development. Further, the company offers silico developability, a profiling toolset for antibody lead candidates; and in vitro analytical tools for the study of critical quality attributes. Additionally, it provides LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; antibody chimerization for cloning and production of variable antibody domain; Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom applications; breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts; and protein manufacturing services. The company is headquartered in Victoria, Canada.", "fullTimeEmployees": 72, "companyOfficers": [{"maxAge": 1, "name": "Dr. Jennifer Lynne Bath Ph.D.", "title": "CEO, President & Non-Independent Director", "fiscalYear": 2024, "totalPay": 734255, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kristin  Taylor CPA, M.B.A.", "title": "Chief Financial Officer", "fiscalYear": 2024, "totalPay": 631974, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ilse  Roodink", "title": "Chief Scientific Officer & Interim General Manager of IPA Europe, Oss", "fiscalYear": 2024, "totalPay": 202257, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David E. Orton", "title": "Chief Operating Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Roland  Romijn", "title": "Head of General Operations of the Utrecht site of IPA (Europe)", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "maxAge": 86400, "priceHint": 4, "previousClose": 0.9245, "open": 0.95, "dayLow": 0.9, "dayHigh": 1.037, "regularMarketPreviousClose": 0.9245, "regularMarketOpen": 0.95, "regularMarketDayLow": 0.9, "regularMarketDayHigh": 1.037, "beta": 0.262, "forwardPE": -7.285714, "volume": 201647, "regularMarketVolume": 201647, "averageVolume": 87138, "averageVolume10days": 153450, "averageDailyVolume10Day": 153450, "bid": 0.9879, "ask": 1.05, "bidSize": 100, "askSize": 100, "marketCap": 27848346, "fiftyTwoWeekLow": 0.58, "fiftyTwoWeekHigh": 2.6, "priceToSalesTrailing12Months": 1.1358327, "fiftyDayAverage": 0.91784, "twoHundredDayAverage": 1.3576, "currency": "USD", "enterpriseValue": 38070304, "profitMargins": -1.10845, "floatShares": 23229855, "sharesOutstanding": 27302300, "sharesShort": 100681, "sharesShortPriorMonth": 139585, "sharesShortPreviousMonthDate": 1719532800, "dateShortInterest": 1722384000, "sharesPercentSharesOut": 0.0037, "heldPercentInsiders": 0.12732, "heldPercentInstitutions": 0.060739998, "shortRatio": 1.52, "shortPercentOfFloat": 0.0037, "bookValue": 1.259, "priceToBook": 0.81016684, "lastFiscalYearEnd": 1714435200, "nextFiscalYearEnd": 1745971200, "mostRecentQuarter": 1714435200, "netIncomeToCommon": -27177000, "trailingEps": -0.77, "forwardEps": -0.14, "lastSplitFactor": "4:1", "lastSplitDate": 1369872000, "enterpriseToRevenue": 1.553, "enterpriseToEbitda": -3.67, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "IPA", "underlyingSymbol": "IPA", "shortName": "ImmunoPrecise Antibodies Ltd.", "longName": "ImmunoPrecise Antibodies Ltd.", "firstTradeDateEpochUtc": 1010413800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "c3f8cba8-b04a-312b-852d-88b521a5debb", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.02, "targetHighPrice": 9.01, "targetLowPrice": 3.0, "targetMeanPrice": 6.01, "targetMedianPrice": 6.01, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 2, "totalCash": 3459000, "totalCashPerShare": 0.127, "ebitda": -10372000, "totalDebt": 13681000, "quickRatio": 0.977, "currentRatio": 1.414, "totalRevenue": 24518000, "debtToEquity": 40.332, "revenuePerShare": 0.956, "returnOnAssets": -0.12784, "returnOnEquity": -0.59258, "freeCashflow": -706000, "operatingCashflow": -4246000, "revenueGrowth": 0.149, "grossMargins": 0.4916, "ebitdaMargins": -0.42304, "operatingMargins": -0.54930997, "financialCurrency": "CAD", "trailingPegRatio": null, "__fetch_time": "2024-08-19"}]